{"id":12604,"date":"2025-06-27T12:00:00","date_gmt":"2025-06-27T16:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=12604"},"modified":"2025-06-26T10:13:22","modified_gmt":"2025-06-26T14:13:22","slug":"long-covid-in-2025-latest-research-symptoms-and-treatment-advances","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=12604","title":{"rendered":"Long COVID in 2025: Latest Research, Symptoms, and Treatment Advances"},"content":{"rendered":"\n<p class=\"has-small-font-size\">By\u00a0Editorial Team\u00a0&#8211;\u00a0<time datetime=\"2025-06-25T08:08:00-07:00\">June 25, 2025<\/time><\/p>\n\n\n\n<p>Long COVID continues to affect millions worldwide in 2025, with ongoing research shedding new light on its causes, symptoms, and potential treatments. This article summarizes the most recent scientific findings and clinical advances to help patients and healthcare providers better understand and manage this complex condition.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/blogger.googleusercontent.com\/img\/b\/R29vZ2xl\/AVvXsEgX2gTEkPNzqlx0c-uw4GAYjARg9fJJxYRB681t89SK2xJKkLfgnE6uMrmzmpNE4u9Ad9jQzRytTmd0jGiLDTrXqPDqFEby3NHR4SJ1dATX12PwK0r8D7Hxolp9n_hORhnYpMuVm5hdRX1zL4o4a_vLEzzi2H7K-UukJfqoiNyblfcvQn8qFbVOC88IczU\/s816\/_-%20visual%20selection%20(18).png\"><img decoding=\"async\" src=\"https:\/\/blogger.googleusercontent.com\/img\/b\/R29vZ2xl\/AVvXsEgX2gTEkPNzqlx0c-uw4GAYjARg9fJJxYRB681t89SK2xJKkLfgnE6uMrmzmpNE4u9Ad9jQzRytTmd0jGiLDTrXqPDqFEby3NHR4SJ1dATX12PwK0r8D7Hxolp9n_hORhnYpMuVm5hdRX1zL4o4a_vLEzzi2H7K-UukJfqoiNyblfcvQn8qFbVOC88IczU\/w640-h480\/_-%20visual%20selection%20(18).png\" alt=\"\"\/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"latest-research-insights-on-long-covid\">Latest Research Insights on Long COVID<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Immune System Markers and Genetic Risk Factors<\/h2>\n\n\n\n<p>A recent clinical study led by Cardiff Metropolitan University and Cwm Taf Morgannwg University Health Board identified elevated levels of the immune protein Interleukin-6 (IL-6) in people suffering from Long COVID compared to those who fully recovered<a href=\"https:\/\/www.cardiffmet.ac.uk\/news\/2025\/new-research-on-long-covid-offers-hope-for-patients-living-with-condition.php\" rel=\"noreferrer noopener\" target=\"_blank\">1<\/a>.&nbsp;The study also found that individuals with a particular IL-6 receptor genotype, known as the \u2018AA\u2019 genotype, have an increased risk of developing Long COVID. These findings suggest IL-6 and its receptor could serve as biomarkers to predict risk and guide future treatments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Large-Scale Data from Electronic Health Records (EHR)<\/h2>\n\n\n\n<p>The RECOVER initiative analyzed over 6 million EHRs and found that between 10% and 26% of adults and 4% of children who had COVID-19 developed Long COVID<a href=\"https:\/\/recovercovid.org\/news\/recover-research-update-june-2025\" rel=\"noreferrer noopener\" target=\"_blank\">2<\/a>.&nbsp;Risk factors include being an adolescent or elderly, female sex, and hospitalization during acute infection. The data also showed that Long COVID incidence rises with the emergence of new SARS-CoV-2 variants, underscoring the ongoing public health challenge.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"common-symptoms-of-long-covid-in-2025\">Common Symptoms of Long COVID in 2025<\/h2>\n\n\n\n<p>Long COVID symptoms vary widely and can affect multiple organ systems. Researchers have identified over 200 symptoms, but the most common and clinically relevant include<a href=\"https:\/\/www.healthdirect.gov.au\/long-covid\" rel=\"noreferrer noopener\" target=\"_blank\">3<\/a><a href=\"https:\/\/newsroom.uw.edu\/news-releases\/researchers-identify-most-common-symptoms-long-covid\" rel=\"noreferrer noopener\" target=\"_blank\">4<\/a>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>General:\u00a0Fatigue, weakness, post-exertional malaise (worsening after activity), hair loss, pain, rash<\/li>\n\n\n\n<li>Respiratory:\u00a0Shortness of breath, chronic cough, chest pain<\/li>\n\n\n\n<li>Cardiovascular:\u00a0Chest tightness, heart palpitations, postural orthostatic tachycardia syndrome (POTS)<\/li>\n\n\n\n<li>Neurological:\u00a0Brain fog, memory loss, difficulty concentrating, headaches, dizziness, loss of smell or taste<\/li>\n\n\n\n<li>Gastrointestinal:\u00a0Abdominal pain, diarrhea, constipation, nausea, heartburn<\/li>\n\n\n\n<li>Muscle and Bone:\u00a0Muscle pain and weakness<\/li>\n\n\n\n<li>Mental Health:\u00a0Anxiety, depression, insomnia, psychosis symptoms<\/li>\n\n\n\n<li>Other:\u00a0Kidney problems, sexual dysfunction, abnormal movements<\/li>\n<\/ul>\n\n\n\n<p>These symptoms may be ongoing, intermittent, or fluctuate in severity, making diagnosis and management challenging.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"advances-in-treatment-options\">Advances in Treatment Options<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Monoclonal Antibody Therapy<\/h2>\n\n\n\n<p>A promising clinical trial underway at Nova Southeastern University is testing sipavibart, a long-acting monoclonal antibody originally approved for COVID-19 prevention, as a treatment for Long COVID<a href=\"https:\/\/www.eurekalert.org\/news-releases\/1082415\" rel=\"noreferrer noopener\" target=\"_blank\">5<\/a>.&nbsp;Early observational studies suggest monoclonal antibodies may reduce or eliminate Long COVID symptoms in some patients, offering hope for a targeted therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Repurposed and Emerging Therapies<\/h2>\n\n\n\n<p>Several non-antiviral treatments show potential based on recent clinical evidence<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11599064\/\" rel=\"noreferrer noopener\" target=\"_blank\">6<\/a>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Metformin:\u00a0Large phase 3 trials demonstrated a 42% to 63% reduction in Long COVID incidence when used early, making it a leading candidate for prevention.<\/li>\n\n\n\n<li>Low-Dose Naltrexone (LDN):\u00a0Shows significant improvements in fatigue, post-exertional malaise, and pain.<\/li>\n\n\n\n<li>Dexamethasone:\u00a0Reduces fatigue and shortens symptom duration by about 33%.<\/li>\n\n\n\n<li>Omega-3 Fatty Acids:\u00a0Moderate benefits for mental health and musculoskeletal symptoms.<\/li>\n\n\n\n<li>L-Arginine with Vitamin C:\u00a0High rates of symptom relief, especially fatigue and shortness of breath.<\/li>\n<\/ul>\n\n\n\n<p>Other treatments under investigation include therapeutic apheresis, intravenous immunoglobulin (IVIg), N-acetylcysteine (NAC), and immunomodulators like anakinra (IL-1 receptor antagonist), fluvoxamine (SSRI with anti-inflammatory effects), and infliximab (TNF inhibitor).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"looking-ahead\">Looking Ahead<\/h2>\n\n\n\n<p>The complexity of Long COVID, with its multi-system involvement and varied symptoms, requires continued research and a multi-pronged treatment approach. Biomarkers like IL-6 and genetic factors may soon help identify at-risk individuals early, enabling preventive strategies. Meanwhile, ongoing clinical trials and real-world data analyses are expanding the arsenal of therapeutic options, bringing hope to millions affected worldwide.<\/p>\n\n\n\n<p>If you or someone you know is experiencing persistent symptoms after COVID-19 infection, consult healthcare professionals for evaluation and management. Early recognition and tailored treatment can improve outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>By\u00a0Editorial Team\u00a0&#8211;\u00a0June 25, 2025 Long COVID continues to affect millions worldwide in 2025, with ongoing research shedding new light on its causes, symptoms, and potential treatments. This article summarizes the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":12617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12604","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/12604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12604"}],"version-history":[{"count":1,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/12604\/revisions"}],"predecessor-version":[{"id":12605,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/12604\/revisions\/12605"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/12617"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}